Trial Profile
Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms PADDLE
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results of 96 weeks presented at the 9th International AIDS Society Conference on HIV Science
- 21 Aug 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2017.